1 July 2013 in Brachytherapy
1 January 2013 in Brachytherapy
Postplan evaluation is essential for quality assurance in prostate brachytherapy. MRI has demonstrated greater interobserver consistency in prostate contouring compared with CT. Although a valuable tool in postimplant assessment, MRI is costly and not always available. Our purpose is to compare dosimetry obtained using fusion of postimplant CT with preimplant transrectal ultrasound (TRUS) vs. CT-MR fusion. Twenty patients receiving permanent (125)I seed prostate brachytherapy underwent preimplant TRUS with urethrography, 1-month CT with a Foley catheter, and 1-month MRI. No patient received androgen deprivation therapy or external beam radiotherapy. The prescription dose of (125)I implant monotherapy was 144Gy. The preimplant TRUS and postimplant CT images were fused based on urethral position, and the CT-TRUS images were subsequently fused to the MRI using a seed-to-seed match. Dosimetric parameters for the ultrasound- and MR-derived prostate were compared. The mean absolute difference between dosimetry from MRI or CT-TRUS fusion for D(90) was 3.2% and in V(100) was 1.2%. Only 1 patient had a difference in MR- and ultrasound-derived D(90) of more than 10% (11.4%) and only 1 had a difference in V(100) of more than 5%. Fusion of preimplant TRUS with 1-month postimplant CT appears to lead to acceptable agreement with MR-based dosimetric parameters in postplan evaluation. TRUS-based volumes may be a reasonable alternative to MRI in settings where MRI is not available.
1 January 2013 in Brachytherapy
We describe a magnetic resonance (MR) scan sequence for prostate brachytherapy postimplant assessment. One brachytherapy team at the British Columbia Cancer Agency has incorporated MR-CT fusion into their permanent seed prostate brachytherapy quality assurance procedure. Several attempts were required to ensure that the diagnostic MR scanner at the adjoining general hospital performed the desired sequence, providing many examples of suboptimal scans and underlining the pitfalls for a center trying to incorporate the use of MR scanning into their brachytherapy program. The recommended sequence (Fast Spin Echo T2-weighted, repetition time [TR]/echo time [TE] 4500/90, echo train length [ETL] 10, 20×20 field of view [FOV], 80 bandwidth [BW]) is associated with superior edge detection when compared with those images in which a typical diagnostic sequence was used. The use of a low bandwidth sequence does not compromise edge detection or seed identification when compared with a higher bandwidth. We have defined a magnetic resonance imaging sequence, which appears to optimize both prostate delineation and identification of seeds, lending itself to straightforward fusion with CT images and allowing for less uncertainty in permanent seed prostate brachytherapy quality assurance.
1 July 2013 in Brachytherapy
28 September 2015 in JMIR Research Protocols
Widespread integration of the Internet has resulted in an increase in the feasibility of using Web-based technologies as a means of communicating with patients. It may be possible to develop secure and standardized systems that facilitate Internet-based patient-reported outcomes which could be used to improve patient care. This study investigates patient interest in participating in an online post-treatment disease outcomes and quality of life monitoring program developed specifically for patients who have received radiation treatment for prostate cancer at a regional oncology center. Patients treated for prostate cancer between 2007 and 2011 (N=1113) at the British Columbia Cancer Agency, Centre for the Southern Interior were invited by mail to participate in a standardized questionnaire related to their post-treatment health. Overall participation rates were calculated. In addition, demographics, access to broadband Internet services, and treatment modalities were compared between participants and nonparticipants. Of the 1030 eligible invitees, 358 (358/1030, 34.7%) completed the online questionnaire. Participation rates were higher in individuals younger than age 60 when compared to those age 60 or older (42% vs 31%) and also for those living in urban areas compared with rural (37% vs 29%) and in those who received brachytherapy versus external beam radiotherapy (EBRT) (41% vs 31%). Better participation rates were seen in individuals who had access to Internet connectivity based on the different types of broadband services (DSL 35% for those with DSL connectivity vs 29% for those without DSL connectivity; cable 35% vs 32%; wireless 38% vs 26%). After adjusting for age, the model indicates that lack of access to wireless broadband connectivity, living in a rural area, and receiving EBRT were significant predictors of lower participation. This study demonstrates that participation rates vary in patient populations within the interior region of British Columbia, especially with older patients, those in rural areas, and those with limited access to quality Internet services.
24 January 2025 in Brachytherapy
High dose rate (HDR) brachytherapy is increasingly adopted for dose escalation in prostate cancer treatment. We report the clinical efficacy and toxicity of HDR prostate brachytherapy combined with external beam radiotherapy (EBRT) and evaluate the predictability of the biochemical definition of cure of 4-year PSA ≤0.2 ng/mL for failure free survival (FFS). A single centre retrospective study was conducted, including all patients with high-tier intermediate risk and high-risk prostate cancer treated with HDR brachytherapy combined with EBRT from 2011 to 2019. Patient and prostate cancer characteristics, treatment, clinical endpoints, and follow up were collected. Total 319 patients were analyzed. The median age was 68 with median follow up of 77.1 months. Total 142 had high-tier intermediate and 177 had high-risk disease. Brachytherapy doses were initially 20 Gy/2 fractions, and subsequently 15 Gy/1 fraction. All patients received 46 Gy/23 fractions of EBRT. Overall survival at 5 and 9 years was 92.2% and 77.0%, respectively. Failure-free survival (FFS) was 86.0% at 5 years and 76.1% at 9 years. PSA ≤ 0.2 ng/mL at 4 years was seen in 79.3% of patients and was associated with FFS of 94.1% at 9 years. Grade 3 urethral stricture, hematuria, or proctitis occurred in 2.8%, 0%, and 0%, respectively. HDR brachytherapy in addition to EBRT is effective treatment for unfavourable localized prostate cancer with a very acceptable toxicity profile. The biochemical definition of cure of PSA < 0.2 ng/mL at 4 years was predictive for FFS at 9 years.